Brightpath Bio is a clinical-stage oncology drug discovery venture focused exclusively on the development of novel cancer immunotherapies. The company's pipeline encompasses three modalities: cell therapies (including iPS cell-derived NKT cell therapies and CAR-T cell therapies), antibody drugs targeting immune checkpoint and immunomodulatory factors, and cancer vaccines. Its business model centers on in-house discovery and early-stage clinical development of cancer immunotherapy candidates, followed by licensing to domestic and international pharmaceutical companies in exchange for upfront payments, development milestones, and sales royalties.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →Brightpath Bio is a clinical-stage oncology drug discovery venture focused exclusively on the development of novel cancer immunotherapies. The company's pipeline encompasses three modalities: cell therapies (including iPS cell-derived NKT cell therapies and CAR-T cell therapies), antibody drugs targeting immune checkpoint and immunomodulatory factors, and cancer vaccines. Its business model centers on in-house discovery and early-stage clinical development of cancer immunotherapy candidates, followed by licensing to domestic and international pharmaceutical companies in exchange for upfront payments, development milestones, and sales royalties.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →